High Response Rates to Crizotinib in Advanced, Chemoresistant ALK-Positive Lymphoma


High Response Rates to Crizotinib in Advanced, Chemoresistant ALK-Positive Lymphoma
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Andrew M Evens, DO, MSc (2/12/14)
Redaelli S et al. High response rates to crizotinib in advanced, chemoresistant ALK+ lymphoma patients. Proc ASH 2013;Abstract 368.

Dr Evens is Professor of Medicine and Chief of the Division of Hematology/Oncology at Tufts Medical Center and Director of the Lymphoma Program and Interim Director at Tufts Cancer Center in Boston, Massachusetts.